Side-by-side · Research reference
HCGvsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED12/52 cited
BFDA-ApprovedFlagship15/53 cited
HCG
Glycoprotein Hormone · LH Mimetic
IM or SQ · 2–3×/week
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
HCG
Semaglutide
Primary target
LH receptors on testicular Leydig cellsSchröder-Lange 2025
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
hCG → Leydig cell LH receptor → Intracellular cAMP → Steroidogenesis pathway activation → Testosterone synthesis
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Downstream effect
Elevated intratesticular testosterone, restored spermatogenesis, virilization, secondary sex characteristic developmentKonsam 2026Zachariou 2026
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
No — exogenous hCG bypasses hypothalamic-pituitary axis; endogenous LH remains suppressed
Glucose-dependent insulin release preserves physiological feedback
Origin
Heterodimeric glycoprotein (alpha subunit shared with LH/FSH/TSH; beta subunit confers specificity). Available as urinary-derived or recombinant formulations.
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
Rare with recombinant; possible with urinary-derived formulations
—
02Dosage Protocols
Parameter
HCG
Semaglutide
Hypogonadotropic hypogonadism (monotherapy)
2,000 IU IM/SQ 2–3×/weekKonsam 2026Zachariou 2026
Titrate to normalize testosterone (300–1,000 ng/dL) or achieve target AMH ~7.4 ng/mL.
—
Combined therapy (hCG + FSH)
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wkKonsam 2026Nariyoshi 2025
Preferred for azoospermia; FSH added after initial hCG phase or from outset.
—
Triple therapy (experimental)
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wk + testosterone 100 mg IM q2wkKonsam 2026
May accelerate virilization; reduces hCG requirements (~30% lower cumulative dose vs monotherapy).
—
Cryptorchidism (pediatric)
500–4,000 IU IM 2–3×/week for 3–6 weeks
—
Evidence basis
RCT / Meta-analysis / FDA-approvedKonsam 2026Huijben 2026
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Duration to sperm appearance
12–24 months (median ~18 mo)Huijben 2026Zachariou 2026
Congenital HH may require longer treatment; acquired HH responds faster.
—
Monitoring
Serum testosterone, semen analysis q3–6mo, testicular ultrasound
Thickened seminiferous tubules (>300 μm) on ultrasound predict imminent sperm appearance.Nariyoshi 2025
—
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
Frequency
—
Once weekly, same day each week
Titration schedule
—
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
Duration
—
Indefinite for chronic indication
Discontinuation results in weight regain.
Reconstitution
—
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Timing
—
Any time of day, with or without food
04Side Effects & Safety
Parameter
HCG
Semaglutide
Injection site reaction
Pain, erythema (mild, transient)
Mild erythema, pruritus
Gynecomastia
Aromatization of elevated testosterone to estradiol; dose-dependent
—
Testicular discomfort / Edema
Rapid testicular growth in hypogonadal males; usually self-limiting
—
Polycythemia
Elevated hematocrit from supraphysiological testosterone; monitor CBC
—
Mood / Libido changes
Variable; usually positive with normalization of testosterone
—
Acne / Oily skin
Androgen-mediated; dose-dependent
—
Prostate concerns
Monitor PSA in older males; hCG restores physiological testosterone (not supraphysiological)
—
Antibody formation
Rare with recombinant; possible with urinary-derived
—
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Heart rate
—
Modest ↑ resting HR (~2-4 bpm)
Absolute Contraindications
HCG
- ·Androgen-dependent malignancy (prostate, breast cancer)
- ·Hypersensitivity to hCG or excipients
- ·Precocious puberty
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
HCG
- ·Untreated obstructive sleep apnea
- ·Severe cardiovascular disease (polycythemia risk)
- ·History of thromboembolism
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
HCG
Semaglutide
1. Reconstitution (if lyophilized)
Add sterile water or bacteriostatic water per manufacturer instructions. Typically 1–2 mL per 5,000–10,000 IU vial. Roll gently — do not shake. Solution should be clear.
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Injection site
Intramuscular: ventrogluteal, vastus lateralis, or deltoid. Subcutaneous: abdomen, avoiding navel (2-inch radius). Rotate sites to prevent lipohypertrophy.
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. Timing
Administer 2–3 times per week. Consistent weekly schedule recommended (e.g., Monday/Thursday or Monday/Wednesday/Friday).
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Storage
Lyophilized: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C. Bacteriostatic water extends shelf life to ~30 days; sterile water use within 72 hours.
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Needle selection
IM: 21–23G, 1–1.5 inch. SQ: 25–27G, 5/8 inch. Inject slowly (30–60 seconds for IM).
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
06Stack Synergy
HCG
— no documented stacks
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)